CCNA2

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Dis

Retrieved on: 
Thursday, December 7, 2023
Phase, C-peptide, Insulin resistance, Poster session, Insulin, Diabetes, Disease, QD, Menin, Glycated hemoglobin, Week, DSM-IV codes, CCNA2, Cancer, Food, PBK, Poster, A1C, Patient, Safety, Gene expression, Pharmaceutical industry

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the full abstract, titled “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control”, will be presented during the Abstract Oral Presentation Session as well as the Poster Session of the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 7-9, 2023.

Key Points: 
  • BMF-219 is the first investigational agent to show durable glycemic control during off-treatment period after four weeks of dosing.
  • These data also further support the potential for BMF-219 as a disease modifying agent in type 2 diabetes.
  • Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.